Medtronic Misses Endeavor Primary Endpoint, But Claims PMA Still On Track

Medtronic maintains that it will submit a PMA for the Endeavor drug-eluting stent on schedule, despite failing to meet its primary endpoint for in-segment late lumen loss in the ENDEAVOR III confirmatory study